Core Viewpoint - PolyPid Ltd. has initiated a New Drug Application (NDA) submission for D-PLEX₁₀₀ to the FDA for preventing surgical site infections in colorectal surgery, with completion expected in the second quarter of 2026 [2][4]. Group 1: NDA Submission Details - The NDA is submitted under the FDA's Fast Track designation, allowing for a rolling review process [3]. - The initial submission includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section to follow in the second quarter of 2026 [3]. Group 2: Product Information - D-PLEX₁₀₀ is designed to provide prolonged and controlled antibacterial activity at the surgical site, utilizing PolyPid's Kynatrix delivery technology to release doxycycline over 30 days [5]. - The product demonstrated a statistically significant 60% relative risk reduction in surgical site infection incidence in the Phase 3 SHIELD II trial [5]. Group 3: Company Overview - PolyPid Ltd. focuses on developing long-acting, controlled-release drugs to address unmet medical needs across various therapeutic areas, including surgical care and metabolic diseases [6]. - The company aims to redefine therapy performance and enhance patient care standards through innovation [6].

Core Insights - PolyPid is targeting an initial label for D-PLEX100 focused on preventing surgical site infections in abdominal colorectal surgery, supported by SHIELD II data and breakthrough therapy designation from the FDA [1] - The FDA has indicated that the existing clinical data package is adequate for NDA submission, providing clarity on submission structure and expectations [2] - The company plans to begin a rolling NDA submission for D-PLEX100 by the end of Q1 2026, with a six-month priority review expected [3][7] Regulatory and Clinical Developments - PolyPid completed its SHIELD II Phase 3 trial in 2025 and is advancing towards regulatory preparation for D-PLEX100, with a new drug application submission planned for early 2026 [4] - The FDA has supported the rolling NDA review path for D-PLEX100, with initial submissions focusing on chemistry, manufacturing, and controls, followed by clinical modules [7] - Management anticipates a European submission approximately one quarter after the FDA filing [9] Financial Overview - As of December 31, 2025, PolyPid reported $12.9 million in cash and a net loss of $34.2 million for the full year, with expectations to fund operations into the second half of 2026 [5][19] - Research and development expenses for Q4 2025 were $6.2 million, down from $7.0 million in the prior year, while general and administrative expenses rose to $1.8 million [17] - Full-year R&D expenses increased to $23.8 million, attributed to activities related to the SHIELD II trial and regulatory preparations [18] Commercial Strategy - The company is advancing U.S. commercial partnership discussions with hospital-focused partners and preparing for pre-launch activities [6][8] - PolyPid's top commercial priority is the U.S. market, with potential interest in other geographies as part of discussions [9] - Management is focusing on building awareness and readiness for D-PLEX100 through market research, pricing work, and external clinical engagement [12][13] Corporate Updates - Brooke Story was appointed as chair of the board in December 2025, bringing experience in medical technology and surgical solutions [14] - PolyPid has rebranded to reflect its transition from an R&D-focused organization to one preparing for commercialization [15] - The company introduced "Kynatrix" as the name for its next-generation technology umbrella, which includes expanded controlled-release capabilities [16]

Financial Data and Key Metrics Changes - For Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase III trial [14] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [15] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the net loss of $8.5 million or $1.13 per share in Q4 2024 [15] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [16] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase III trial, with D-PLEX100 meeting its primary and key secondary endpoints [6] - The company is advancing its long-acting GLP-1 receptor agonist program alongside D-PLEX100 [6] Market Data and Key Metrics Changes - The company received positive feedback from the FDA regarding the regulatory pathway for D-PLEX100, supporting a rolling NDA submission expected to begin by the end of Q1 2026 [7] - The company is in advanced stages of partnership discussions in the U.S., reflecting recognition of D-PLEX100's strong clinical profile [8] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a focus on regulatory pathways and commercial partnerships [6][10] - The introduction of Kynatrix technology represents an expansion of the company's capabilities beyond localized delivery, targeting systemic therapeutic needs [13] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be a transformative year, with the rolling NDA submission and ongoing partnership discussions [9] - The company is preparing for market approval and launch, emphasizing the importance of building awareness and readiness among stakeholders [30] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session All Questions and Answers Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, supported by Phase III data [21] Question: Any thoughts on plans for a broader label or further expansion opportunities for D-PLEX100? - The company plans to meet with the FDA to discuss potential label expansion opportunities during the review process [23] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on market research, building awareness, and creating a KOL network to prepare for commercialization [31] Question: How do you think about strategic partnerships for the GLP-1 program? - The company aims to partner at an early stage, leveraging robust preclinical data to attract interest from potential partners [34] Question: What factors will play a role in identifying the final partner for D-PLEX100? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite, essential for marketing the product [40] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [48]

Financial Data and Key Metrics Changes - For Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase 3 trial [14] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024 [15] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, compared to a net loss of $8.5 million or $1.13 per share in Q4 2024 [15] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [16] - As of December 31, 2025, the company had $12.9 million in cash and equivalents [16] Business Line Data and Key Metrics Changes - The company advanced D-PLEX100 into final stages of regulatory preparation after successful Phase 3 trial results [6][7] - Marketing and business development expenses for the year increased to $2 million from $0.9 million in 2024, reflecting increased efforts as the company moves closer to commercialization [16] Market Data and Key Metrics Changes - The company is focusing on the U.S. market for D-PLEX100, with plans for NDA submission expected by the end of Q1 2026 [9][39] - Discussions with potential U.S. commercial partners are advancing, reflecting the strong clinical profile of D-PLEX100 [11] Company Strategy and Development Direction - The company aims to transition from a primarily R&D-focused organization to one preparing for commercialization [12] - The introduction of Kynatrix technology represents a broader long-term opportunity, while D-PLEX100 remains the focus for near-term execution [13] - The company is engaging with external stakeholders, including surgeons and hospital administrators, to build awareness and readiness for market approval [9][12] Management Comments on Operating Environment and Future Outlook - Management believes 2026 could be transformative, with the rolling NDA submission expected to begin soon and ongoing partnership discussions [9] - Positive feedback from the FDA supports the regulatory pathway for D-PLEX100, indicating that existing clinical data is adequate for NDA submission [21][44] Other Important Information - The company appointed Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] - The company is preparing for commercial readiness, including market research and building a KOL network [31] Q&A Session Summary Question: Scope of the label for D-PLEX100 - Management is targeting an initial label for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, with potential for broader applications [21][22] Question: Plans for broader label and expansion opportunities - Management is planning to meet with the FDA to discuss potential label expansion as part of their ongoing strategy [23] Question: Preparation for potential approval of D-PLEX100 - The company is focused on building awareness, preparing packaging, and conducting market research to ensure readiness for commercial launch [30] Question: Strategic plans for GLP-1 program - The GLP-1 program aims for improved patient compliance with a sustained release mechanism, with plans to partner at an early stage [33] Question: Factors influencing partnership discussions - The ideal partner will have hospital-based capabilities and presence in the surgical suite, which is crucial for marketing D-PLEX100 [40] Question: Timeline for rolling submission - The NDA submission is expected to begin by the end of Q1 2026, with a shortened review period anticipated due to Fast Track and Breakthrough Therapy Designation [56]

Financial Data and Key Metrics Changes - In Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase 3 trial [15] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [16] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the previous year but improved on a per-share basis from $1.13 in Q4 2024 [16] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [17] - As of December 31, 2025, the company had $12.9 million in cash and equivalents, with additional gross proceeds of $3.7 million generated from warrant exercises post-quarter [18] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase 3 trial for D-PLEX100, achieving its primary and key secondary endpoints [5] - The focus remains on advancing the regulatory pathway for D-PLEX100 and commercial partnership discussions in the U.S. [5][7] Market Data and Key Metrics Changes - The company is engaging with potential U.S. commercial partners that have strong hospital-based commercialization experience [11] - Discussions with partners have progressed to advanced stages, reflecting the strong clinical profile of D-PLEX100 [7] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a renewed corporate brand to reflect this change [11][12] - The introduction of Kynatrix technology aims to expand capabilities beyond localized delivery, targeting metabolic diseases with a long-acting GLP-1 receptor agonist program [14] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be transformative, with the rolling NDA submission expected to begin by the end of Q1 2026 [9] - Positive feedback from the FDA supports the regulatory pathway for D-PLEX100, with expectations for a rolling NDA submission [6][9] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session Summary Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in abdominal colorectal surgery, supported by Phase 3 data [22] Question: Any thoughts on plans for broader label expansion? - There may be opportunities for label expansion into broader abdominal surgical applications as the review process progresses [24] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on building awareness, market research, and creating a KOL network to prepare for commercialization [32] Question: How do you view the strategic timing for the GLP-1 program? - The company plans to partner at an early stage, leveraging robust preclinical data to attract interest [35] Question: What factors will play a role in identifying the final partner? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite [41] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [50]